The Peptide Addict Intel briefing

One weekly email. Seven sections. Zero hype.

What’s in every issue

1. The one thing that mattered most this week — the single most important development in the peptide space.
2. Study of the week — a new piece of human evidence worth knowing about, with context on what it does and doesn’t prove.
3. Regulatory watch — what changed in approval status, compounding rules, enforcement, or access.
4. Vendor / market shift — quality signals, reputation changes, and operational developments across the vendor landscape.
5. One myth we need to retire — a common claim that the evidence does not support.
6. Best recent article — the most useful long-form piece we published this week.
7. What we’re watching next — the signals on our radar for the weeks ahead.

Voice

More direct and timely than the main site. Still evidence-first. Still anti-hype. Still calm.

When it sends

Once a week. No second emails. No “special offers.” No sales funnels. You will only hear from us on the day the briefing goes out.

Subscribe below

The form at the bottom of this page (and every page) will add you to the list. First briefing hits your inbox next week.